Pharmazz, Inc. registers Phase 3 study of sovateltide for acute traumatic brain injury
The study, titled RESTORE-TBI, plans to enroll 214 participants and is scheduled to begin in December 2026. It is a prospective, multicenter, randomized, double-blind, placebo-controlled Phase III trial evaluating the efficacy and safety of sovateltide (IRL-1620) in patients with traumatic brain injury.
Primary source
ClinicalTrials.gov registry record, October 6, 2026
Phase 3 Evaluation of Sovateltide for the Treatment of Acute Traumatic Brain Injury
Read the source: Phase 3 Evaluation of Sovateltide for the Treatment of Acute Traumatic Brain Injury clinicaltrials.gov
Machine-summarized from the source above; not independently reported. How we use automation